Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenical Rx-To-OTC Switch Filing Slated For This Year

This article was originally published in The Pink Sheet Daily

Executive Summary

A 2005 filing for over-the-counter sale of the obesity agent would be one year earlier than previously expected. GlaxoSmithKline has conducted double-blind, placebo-controlled trials with an orlistat 60 mg dose and has received “good encouragement” from FDA, CEO Garnier says.
Advertisement

Related Content

GSK Begins Detailing Xenical Ahead Of OTC Switch Opportunity
GSK Begins Detailing Xenical Ahead Of OTC Switch Opportunity
Lotensin, Xenical, Brevibloc Need Continued Pediatric AE Monitoring – Committee
Lotensin, Xenical, Brevibloc Need Continued Pediatric AE Monitoring – Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS061570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel